EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Glucocorticoid reduction after starting crinecerfont in adult patients with classic CAH: practical perspectives

Oksana Hamidi iD, Richard J Auchus, Ricardo Correa, Alice C Levine iD, Margaret E Wierman iD, Andrea L Hartzell, Vivian H Lin, Irina Bancos iD

The Journal of Clinical Endocrinology & Metabolism · 17.06.2026 · 111 (7) · 1801-1812

DOI: 10.1210/clinem/dgag147 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 01.04.2026. Verfasst von Oksana Hamidi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital, Glucocorticoids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Neurocrine Biosciences, Inc., NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Crinecerfont, a first-in-class corticotropin-releasing factor type 1 receptor antagonist, is FDA-approved as an adjunct to the physiologic glucocorticoid (GC) required to treat the underlying adrenal insufficiency in patients (≥4 years old) with classic congenital adrenal hyperplasia (CAH). By reducing elevated adrenocorticotropic hormone, crinecerfont controls excess adrenal androgens, thereby enabling lower GC doses. However, there are no published recommendations for how to reduce supraphysiologic GC doses after initiating crinecerfont. This manuscript aims to provide a framework developed by experienced endocrinologists for reducing supraphysiologic GC doses in patients taking crinecerfont. Evidence Acquisition An experienced panel of 11 endocrinologists discussed strategies and considerations when reducing GC doses and developed an algorithm to guide GC dose reductions after introducing crinecerfont in adults with CAH. Evidence Synthesis Approaches to GC reduction should be individualized based on the patient's therapeutic goals, cortisol needs, lifestyle preferences, and the clinician's experience to set appropriate targets for clinical parameters, androgens, and GC dose regimen. In general, GC doses should be reduced gradually to minimize the risks of developing symptoms of GC withdrawal or adrenal insufficiency. GC doses should be adjusted to the lowest level needed to maintain androgens at goal, without reducing below what is needed for cortisol replacement. Practical considerations during GC dose reduction include switching from longer- to shorter-acting GCs (eg, from dexamethasone to hydrocortisone), optimizing dose distribution to mimic normal circadian cortisol exposure, and consolidating or eliminating doses to improve adherence.

Conclusion

This framework for reducing supraphysiologic GC doses in adult patients taking crinecerfont may become increasingly relevant as treatment of CAH shifts toward physiologic GC replacement with adjunctive control of adrenal androgens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Hyperplasia, CongenitalGlucocorticoidsAdultHumansPractice Guidelines as TopicAminesThiazoles

Stichwörter der Autor:innen

17-hydroxyprogesterone21-hydroxylase deficiencyandrostenedionecongenital adrenal hyperplasiacrinecerfontglucocorticoid

Substanzen

crinecerfontGlucocorticoidsAminesThiazoles

Autor:innen und Institutionen

  • Division of Endocrinology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Division of Metabolism, Endocrinology, and Diabetes, Departments of Internal Medicine and Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
  • Endocrinology and Metabolism Section, Medicine Service, LTC Charles S. Kettles Veterans Affairs Medical Center, Ann Arbor, MI 48105, USA.
  • Department of Endocrinology, Medical Specialty Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
  • Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Departments of Medicine, Integrative Physiology, and OBGYN, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

ORCID-Profile: Oksana Hamidi, Alice C Levine, Margaret E Wierman, Irina Bancos

Förderung

  • Neurocrine Biosciences, Inc.
  • NIDDK NIH HHS

Zitieren

APA

Hamidi, O., Auchus, R. J., Correa, R., Levine, A. C., Wierman, M. E., Hartzell, A. L., Lin, V. H., & Bancos, I. (2026). Glucocorticoid reduction after starting crinecerfont in adult patients with classic CAH: practical perspectives. The Journal of Clinical Endocrinology & Metabolism, 111(7), 1801-1812. https://doi.org/10.1210/clinem/dgag147

Vancouver

Hamidi O, Auchus RJ, Correa R, Levine AC, Wierman ME, Hartzell AL, et al. Glucocorticoid reduction after starting crinecerfont in adult patients with classic CAH: practical perspectives. The Journal of Clinical Endocrinology & Metabolism. 2026;111(7):1801-1812. doi:10.1210/clinem/dgag147

BibTeX
@article{Hamidi2026,
  author = {Hamidi, Oksana and Auchus, Richard J and Correa, Ricardo and Levine, Alice C and Wierman, Margaret E and Hartzell, Andrea L and Lin, Vivian H and Bancos, Irina},
  title = {Glucocorticoid reduction after starting crinecerfont in adult patients with classic CAH: practical perspectives},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {7},
  pages = {1801--1812},
  doi = {10.1210/clinem/dgag147}
}
Kostenlos starten →